Advertisement
Home Tags Kidney Problems: Misc.

Tag: Kidney Problems: Misc.

Sotagliflozin

Addition of Sotagliflozin for T1DM Alters Renal Hemodynamics

Addition of SOTA tied to reductions in estimated glomerular filtration rate, blood pressure
Intracranial aneurysms are detected in 9 percent of patients with autosomal dominant polycystic kidney disease undergoing magnetic resonance angiography screening

Brain Aneurysm Risk Examined in Polycystic Kidney Disease

Aneurysms detected by presymptomatic screening, more frequent in those with hypertension, smoking

July 2019 Briefing – Nephrology

Here are what the editors at HealthDay consider to be the most important developments in Nephrology for July 2019. This roundup includes the latest...
Women with preeclampsia have an increased risk for developing end-stage kidney disease (ESKD)

Preeclampsia History Increases Risk for End-Stage Kidney Disease

ESKD risk highest for women with preterm preeclampsia and/or preeclampsia in two pregnancies
Roxadustat is noninferior to epoetin alfa for increasing hemoglobin levels among patients with anemia who are undergoing dialysis

Roxadustat Noninferior to Epoetin Alfa in Dialysis Patients

And for anemia in patients with kidney disease not undergoing dialysis, roxadustat is superior to placebo
For patients with end-stage kidney disease

Bariatric Surgery Up in Patients With End-Stage Kidney Disease

Complication rates similar for patients with, without ESKD undergoing laparoscopic sleeve gastrectomy
In children with end-stage renal disease

Higher eGFR at Dialysis Initiation Tied to Lower Survival in Children

Findings seen among children with end-stage renal disease
Home dialysis use increased from 2005 to 2013

Narrowing Seen in Racial/Ethnic Differences in Home Dialysis Use

Home dialysis use increased in all groups; racial, ethnic differences decreased from 2005 to 2013
In patients with membranous nephropathy at high risk for progressive disease

Rituximab Noninferior to Cyclosporine in Membranous Nephropathy

Drug found to be superior in maintaining proteinuria remission for up to 24 months
Non-vitamin K oral anticoagulants have a superior benefit-risk profile to that of vitamin K antagonists for patients with early-stage chronic kidney disease

Non-Vitamin K Oral Anticoagulants May Be Best for Early-Stage CKD

Benefit-risk profile superior to vitamin K antagonists for early-stage chronic kidney disease